JWH-046

JWH-046_structure.png Chemical structure of JWH-046

JWH-046 is a synthetic cannabinoid that acts as a potent agonist at the CB1 and CB2 cannabinoid receptors. It is part of the naphthoylindole family of compounds, which were first synthesized by John W. Huffman and his team at Clemson University in the 1990s. JWH-046 is one of many compounds in the JWH series, which have been used in scientific research to study the endocannabinoid system.

Chemical Structure and Properties

JWH-046 has the chemical formula C₄H₂₃NO and a molecular weight of 341.45 g/mol. The compound is characterized by a naphthoyl group attached to an indole core, with a pentyl chain at the 1-position of the indole. This structure is similar to other synthetic cannabinoids, which often mimic the structure of tetrahydrocannabinol (THC), the primary psychoactive component of cannabis.

Pharmacology

JWH-046 acts as a full agonist at both the CB1 and CB2 receptors, with a higher affinity for the CB1 receptor. The activation of these receptors by JWH-046 leads to a range of effects, including alterations in mood, perception, and cognition, similar to those produced by THC. However, the potency and efficacy of JWH-046 can vary significantly from THC and other cannabinoids.

Legal Status

The legal status of JWH-046 varies by country. In many jurisdictions, it is classified as a controlled substance due to its potential for abuse and lack of medical use. The compound is often included in legislation targeting synthetic cannabinoids, which are frequently sold as "legal highs" or "herbal incense."

Research and Applications

JWH-046, like other synthetic cannabinoids, has been used in research to better understand the endocannabinoid system and its role in various physiological processes. Studies involving JWH-046 can provide insights into receptor binding, signal transduction, and the potential therapeutic applications of cannabinoid receptor modulation.

Safety and Toxicity

The safety profile of JWH-046 is not well-established, as it has not been extensively studied in humans. Synthetic cannabinoids, in general, have been associated with a range of adverse effects, including tachycardia, hypertension, hallucinations, and psychosis. The use of JWH-046 outside of a controlled research setting is not recommended due to these potential risks.

Also see

• Synthetic cannabinoids
• JWH-018
• Endocannabinoid system
• Cannabinoid receptor
• John W. Huffman